Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia.

Cancer letters - 1 Mar 2020

Gupta Pranav, Zhang Guan-Nan, Barbuti Anna Maria, Zhang Xin, Karadkhelkar Nishant, Zhou Jingfeng, Ding Ke, Pan Jingxuan, Yoganathan Sabesan, Yang Dong-Hua, Chen Zhe-Sheng

Abstract excerpt

Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm primarily due to the presence of the BCR-ABL fusion gene that produces the constitutively active protein, BCR-ABL. Imatinib, a BCR-ABL-targeted drug, is a first-line drug for the treatment of CML. Resistance to imatinib occurs as a result of mutations in the BCR-ABL kinase domains. In this study, we evaluated S116836, a novel BCR-ABL inhibitor, for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 31837444
DOI: 10.1016/j.canlet.2019.11.040

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia.PMID 31837444Read ↗

HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.Semantic proximity Read ↗

HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.Semantic proximity Read ↗

PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.Semantic proximity Read ↗

Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia.Semantic proximity Read ↗

Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).Semantic proximity Read ↗

Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation.Semantic proximity Read ↗

Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation.Semantic proximity Read ↗

MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.Semantic proximity Read ↗

Targeting SOS1 synergistically enhances efficacy of BCR/ABL tyrosine kinase inhibitors and overcomes resistance in chronic myeloid leukemiaSemantic proximity Read ↗

[Recent Advance of Newly Therapy for Chronic Myeloid Leukemia with BCR-ABLT315I Mutation--Review].Semantic proximity Read ↗

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia.Semantic proximity Read ↗

Structure optimization, synthesis and bioactivity evaluation of novel BCR-ABL tyrosine kinase inhibitor targeting T315I mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.